This application relates to compounds having inverse agonist functional selectivity for GABA A receptors containing the α5 subunit for use as a medicament in the treatment of cognitive impairments in subjects suffering from Down syndrome. The present application also relates to the use of compounds having inverse agonist functional selectivity for GABA A receptors containing the α5 subunit for the preparation of a medicament in the treatment of cognitive impairments in subjects suffering from Down syndrome. The application further relates to pharmaceutical compositions for treating cognitive impairments in subjects suffering from Down syndrome comprising a compound having inverse agonist functional selectivity for GABA A receptors containing the α5 subunit, or suitable pharmaceutically acceptable salt thereof, a polyethoxylated castor oil and dimethyl sulfoxide (DMSO). The present application also describes methods for enhancing cognitive function, or treating or lessening the severity of cognitive impairments, in subjects suffering from Down syndrome by administering to a subject in need thereof a pharmaceutically effective amount of one or more compounds having inverse agonist functional selectivity for GABA A receptors containing the α5 subunit. More particularly, the present application is concerned with the treatment of cognitive impairments, such as impairment in memory, learning capacity or both, in subjects suffering from Down syndrome.Linvention concerne des composés ayant une sélectivité fonctionnelle agoniste inverse pour les récepteurs GABA A contenant la sous-unité α5 pour une utilisation comme médicament dans le traitement des troubles cognitifs chez les sujets souffrant du syndrome de Down. La présente invention concerne également lutilisation de composés ayant une sélectivité fonctionnelle agoniste inverse pour les récepteurs GABA A contenant la sous-unité α5 pour la préparation dun médicament destiné au traitement des troubles cognitifs chez les suj
